{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:00:50Z","timestamp":1772809250571,"version":"3.50.1"},"reference-count":7,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2001,5,1]],"date-time":"2001-05-01T00:00:00Z","timestamp":988675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2001,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The antimicrobial activity of BMS 284756, a novel des-F(6)-quinolone, was comparatively evaluated against 257\n            <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n            , 198\n            <jats:italic>Haemophilus influenzae<\/jats:italic>\n            , and 88\n            <jats:italic>Moraxella catarrhalis<\/jats:italic>\n            strains isolated in Latin America between July and September of 1999 as part of the SENTRY Antimicrobial Surveillance Program. Nearly 28.0% of\n            <jats:italic>S. pneumoniae<\/jats:italic>\n            strains were nonsusceptible to penicillin. The rank order of quinolone potency versus\n            <jats:italic>S. pneumoniae<\/jats:italic>\n            was BMS 284756 (MIC at which 90% of isolates were inhibited [MIC\n            <jats:sub>90<\/jats:sub>\n            ], 0.12 \u03bcg\/ml) &gt; trovafloxacin (MIC\n            <jats:sub>90<\/jats:sub>\n            , 0.25 \u03bcg\/ml) &gt; gatifloxacin (MIC\n            <jats:sub>90<\/jats:sub>\n            , 0.5 \u03bcg\/ml) &gt; levofloxacin and ciprofloxacin (MIC\n            <jats:sub>90<\/jats:sub>\n            , 1 to 2 \u03bcg\/ml). All\n            <jats:italic>S. pneumoniae<\/jats:italic>\n            strains that were not susceptible to other quinolones were inhibited by BMS 284756 at \u22642 \u03bcg\/ml. The overall prevalence of \u03b2-lactamase production was 15.2% in\n            <jats:italic>H. influenzae<\/jats:italic>\n            and 98.9% in\n            <jats:italic>M. catarrhalis.<\/jats:italic>\n            BMS 284756 showed excellent potency and spectrum against this group of pathogens, inhibiting all isolates at \u22640.12 \u03bcg\/ml. BMS 284756 exhibited activity similar to those displayed by the new fluoroquinolones, such as levofloxacin, trovafloxacin, or gatifloxacin, and could be a therapeutic option for empirical treatment of community-acquired respiratory tract infections.\n          <\/jats:p>","DOI":"10.1128\/aac.45.5.1463-1466.2001","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T05:56:57Z","timestamp":1027749417000},"page":"1463-1466","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":19,"title":["Activities of BMS 284756 (T-3811) against\n            <i>Haemophilus influenzae<\/i>\n            ,\n            <i>Moraxella catarrhalis<\/i>\n            , and\n            <i>Streptococcus pneumoniae<\/i>\n            Isolates from SENTRY Antimicrobial Surveillance Program Medical Centers in Latin America (1999)"],"prefix":"10.1128","volume":"45","author":[{"name":"SENTRY Participants Group (Latin America)","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Gales","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->University of Iowa College of Medicine, Iowa City, Iowa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio","family":"Sader","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->University of Iowa College of Medicine, Iowa City, Iowa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->University of Iowa College of Medicine, Iowa City, Iowa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"639","article-title":"Comparison of the antibacterial activities of the quinolones BAY 12-8039, gatifloxacin (AM1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.","volume":"40","author":"Bauernfeind A.","year":"1997","unstructured":"Bauernfeind A. Comparison of the antibacterial activities of the quinolones BAY 12-8039, gatifloxacin (AM1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J. Antimicrob. Chemother. 40 1997 639 651","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(99)00020-6"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.2.385"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.6.1999-2002.1999"},{"key":"e_1_3_2_6_2","unstructured":"National Committee for Clinical Laboratory Standards\n          Methods for dilution antimicrobial tests for bacteria that grow aerobically. Approved standard M7\u2013A5.\n          2000\n          National Committee for Clinical Laboratory Standards\n          Wayne Pa"},{"key":"e_1_3_2_7_2","unstructured":"National Committee for Clinical Laboratory Standards\n          Performance standards for antimicrobial susceptibility testing. Supplement tables M100\u2013S10.\n          2000\n          National Committee for Clinical Laboratory Standards\n          Wayne Pa"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.5.1077"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.45.5.1463-1466.2001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.45.5.1463-1466.2001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T12:29:38Z","timestamp":1645446578000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.45.5.1463-1466.2001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5]]},"references-count":7,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2001,5]]}},"alternative-id":["10.1128\/AAC.45.5.1463-1466.2001"],"URL":"https:\/\/doi.org\/10.1128\/aac.45.5.1463-1466.2001","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,5]]},"assertion":[{"value":"2000-08-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-02-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}